Advanced or Metastatic Cholangiocarcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : April 14, 2026
- Updated On : June 17, 2026
- Pages : 154
Advanced or Metastatic Cholangiocarcinoma Market Outlook
Thelansis’s “Advanced or Metastatic Cholangiocarcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Cholangiocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced or Metastatic Cholangiocarcinoma Overview
Advanced or metastatic cholangiocarcinoma is an aggressive malignancy arising from bile duct epithelial cells, classified as intrahepatic, perihilar, or distal subtypes. Most patients present with advanced disease defined by jaundice and weight loss, necessitating mandatory next-generation sequencing at diagnosis. First-line care centers on chemo-immunotherapy backbones, utilizing either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) combined with gemcitabine and cisplatin. For subsequent lines of therapy, management is heavily biomarker-driven. Approved FGFR2 inhibitors like pemigatinib and futibatinib address fusion-positive variants, while ivosidenib targets IDH1 mutations. For HER2-positive phenotypes, the bispecific antibody Ziihera (zanidatamab) serves as the approved targeted standard. Additionally, the therapeutic landscape has expanded to include Bizengri (zenocutuzumab), an approved dual HER2/HER3-targeted bispecific antibody specifically indicated for tumors harboring neuregulin 1 (NRG1) gene fusions. Other targeted subsets include dabrafenib-trametinib for BRAF V600E mutations, larotrectinib or entrectinib for NTRK fusions, and pembrolizumab monotherapy for MSI-H tumors. Multidisciplinary tumor board evaluation, clinical trial enrollment, and early palliative care integration remain indispensable to comprehensive patient management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced or Metastatic Cholangiocarcinoma Market Outlook
Thelansis’s “Advanced or Metastatic Cholangiocarcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Cholangiocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced or Metastatic Cholangiocarcinoma Overview
Advanced or metastatic cholangiocarcinoma is an aggressive malignancy arising from bile duct epithelial cells, classified as intrahepatic, perihilar, or distal subtypes. Most patients present with advanced disease defined by jaundice and weight loss, necessitating mandatory next-generation sequencing at diagnosis. First-line care centers on chemo-immunotherapy backbones, utilizing either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) combined with gemcitabine and cisplatin. For subsequent lines of therapy, management is heavily biomarker-driven. Approved FGFR2 inhibitors like pemigatinib and futibatinib address fusion-positive variants, while ivosidenib targets IDH1 mutations. For HER2-positive phenotypes, the bispecific antibody Ziihera (zanidatamab) serves as the approved targeted standard. Additionally, the therapeutic landscape has expanded to include Bizengri (zenocutuzumab), an approved dual HER2/HER3-targeted bispecific antibody specifically indicated for tumors harboring neuregulin 1 (NRG1) gene fusions. Other targeted subsets include dabrafenib-trametinib for BRAF V600E mutations, larotrectinib or entrectinib for NTRK fusions, and pembrolizumab monotherapy for MSI-H tumors. Multidisciplinary tumor board evaluation, clinical trial enrollment, and early palliative care integration remain indispensable to comprehensive patient management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)